{"id":"W4400272169","doi":"10.1200/jco.2024.42.16_suppl.9559","title":"Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network; Centre Hospitalier de l’Université de Montréal; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Lenvatinib; Oncology; Melanoma; Internal medicine; Phases of clinical research; Clinical trial; Dermatology; Immunotherapy; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001901281,0.0006687734,0.001355548,0.0004625104,0.0004245526,0.001068803,0.0005479484,0.0008083277,0.00163964],"category_scores_gemma":[0.001304368,0.0004748398,0.001585371,0.0006571283,0.0003033821,0.000987983,0.0006366531,0.001493727,0.0003324426],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001304154,"about_ca_system_score_gemma":0.001074428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002101682,"about_ca_topic_score_gemma":0.003770049,"domain_scores_codex":[0.9993677,0.0002336032,0.00005835321,0.0001413399,0.000089348,0.0001097021],"domain_scores_gemma":[0.9992612,0.0001216051,0.0002533664,0.0000498507,0.00005102504,0.0002630326],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4929135,0.01908588,0.3383611,0.001071671,0.00845842,0.000909993,0.000433853,0.002833513,0.01088647,0.0001072673,0.005352641,0.1195858],"study_design_scores_gemma":[0.1260325,0.1879697,0.6659364,0.0002052363,0.005760822,0.001096985,0.0003037164,0.002480012,0.001594873,0.0002212376,0.008312114,0.00008642224],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955673,0.001977779,0.0001324718,0.0001498123,0.00003838092,0.0003312644,0.001147949,0.00001542296,0.0006397351],"genre_scores_gemma":[0.9939383,0.001061186,0.0003409562,0.0004283655,0.00007772458,0.0003337769,0.003149496,0.000005425872,0.0006646827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002101682,"threshold_uncertainty_score":0.01005507,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07907522718799255,"score_gpt":0.4350888136354387,"score_spread":0.3560135864474461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}